Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2The application follows guidance provided to IMUNON in Pre-IND meeting with the FDA
IMUNON Files IND Application to Begin Human Testing of IMNN-101
